OncoMatch/Clinical Trials/NCT06848465

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Is NCT06848465 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including XELOX and Tislelizumab for colorectal cancer.

Phase 1RecruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06848465Data as of May 2026

Treatment: XELOX · Tislelizumab — In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Biomarker criteria

Required: MMR proficient mismatch repair

Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum

Required: MSI microsatellite stable

Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum

Disease stage

Required: Stage T3-4NX, TXN1-2

Metastatic disease required

The clinical baseline stage of rectal cancer assessed by MRI/CT/Transrectal ultrasound was T3-4Nx or TXN1-2

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: investigational drug

Received any of the following treatments: any investigational drug

Cannot have received: anti-tumor vaccine

received anti-tumor vaccines

Cannot have received: live vaccine

received ... live vaccines

Lab requirements

Blood counts

white blood cells ≥ 4.0 × 10^9 cells per l, neutrophils ≥ 1.5 × 10^9 cells per l, hemoglobin ≥ 90 g/l, platelets ≥ 100 × 10^9 cells per l

Kidney function

serum creatinine ≤ 1.5 × uln or glomerular filtration rate > 60 ml/min, based on cockcroft-gault

Liver function

total serum bilirubin ≤ 1.5 × upper limit of normal, alanine aminotransferase or aspartate aminotransferase ≤ 2.5 × upper limit of normal

Cardiac function

left ventricular ejection fractions > 50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify